FMR CORP 13D and 13G filings for Poseida Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-07 10:23 am Sale |
2025-01-31 | 13G | Poseida Therapeutics, Inc. PSTX |
FMR CORP | 0 0.000% |
-10,011,617 (Position Closed) |
Filing |
| 2025-02-07 10:06 am Sale |
2024-12-31 | 13G | Poseida Therapeutics, Inc. PSTX |
FMR CORP | 10,011,617 10.300% |
-4,332,048 (-30.20%) |
Filing |
| 2024-02-09 09:28 am Purchase |
2024-02-08 | 13G | Poseida Therapeutics, Inc. PSTX |
FMR CORP | 14,343,665 14.999% |
1,451,258 (+11.26%) |
Filing |
| 2023-02-09 12:31 pm Purchase |
2023-02-09 | 13G | Poseida Therapeutics, Inc. PSTX |
FMR CORP | 12,892,407 14.999% |
3,516,466 (+37.51%) |
Filing |
| 2022-02-09 10:24 am Purchase |
2022-02-08 | 13G | Poseida Therapeutics, Inc. PSTX |
FMR CORP | 9,375,941 14.999% |
102,940 (+1.11%) |
Filing |
| 2021-02-08 10:31 am Purchase |
2021-02-05 | 13G | Poseida Therapeutics, Inc. PSTX |
FMR CORP | 9,273,001 14.999% |
619 (+0.01%) |
Filing |
| 2020-08-10 09:25 am Purchase |
2020-08-07 | 13G | Poseida Therapeutics, Inc. PSTX |
FMR CORP | 9,272,382 14.999% |
9,272,382 (New Position) |
Filing |